I sold MDGL at 112 in the recent run up as the NASH market size is reduced by Novo oral glp-1 agonist, AMRN positive Adcom which leads to expanded label, NVS buyout MDCO (better marketing push).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.